Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance and PK of [14C]-azetukalner in healthy males
NCT04952467Phase 1Completed
- Sponsor
- Xenon Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azetukalner in focal epilepsy, sponsored by Xenon Pharmaceuticals. Primary endpoint: Total radioactivity excreted in urine and faeces at Day 57. Started Jul 2021; status: completed.
02
Drugs
azetukalner
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT04952467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952467.